246 results match your criteria Other Myeloid Related Precursor Neoplasms


[Clinicopathological features of T-lymphoblastic lymphoma with Langerhans cell histiocytosis in the same lymph node].

Zhonghua Bing Li Xue Za Zhi 2020 Feb;49(2):149-155

Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.

To investigate the clinicopathological features, immunophenotypes, genetics and prognosis of T-lymphocyte lymphoma/myeloid sarcoma combined with Langerhans cell histiocytyosis (coexistence of T-LBL/MS and LCH). Clinical and pathological data of the 6 patients with coexistence of T-LBL/MS and LCH were analyzed, who were diagnosed at the Foshan Hospital of Sun Yat-sen University and the Friendship Hospital of Capital Medical University, from December 2013 to April 2019. The hematoxylin and eosin stain, immunohitochemistry (EnVision) and in situ hybridization were used. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0529-5807.2020.02.009DOI Listing
February 2020

B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review.

BMC Cancer 2019 Nov 27;19(1):1147. Epub 2019 Nov 27.

Floyd and Delores Jones Cancer Institute, Virginia Mason Medical Center, 1100 Ninth Avenue (C2-HEM), Seattle, WA, 98101, USA.

Background: The advent of the immunomodulatory imide drugs (IMiDs) lenalidomide and thalidomide for the treatment of patients with plasma cell myeloma (PCM), has contributed to more than a doubling of the overall survival of these individuals. As a result, PCM patients join survivors of other malignancies such as breast and prostate cancer with a relatively new clinical problem - second primary malignancies (SPMs) - many of which are a result of the treatment of the initial cancer. PCM patients have a statistically significant increased risk for acute myeloid leukemia (AML) and Kaposi sarcoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-6286-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882354PMC
November 2019

Differential network analysis and protein-protein interaction study reveals active protein modules in glucocorticoid resistance for infant acute lymphoblastic leukemia.

Mol Med 2019 08 1;25(1):36. Epub 2019 Aug 1.

Laboratory of Systems Biology and Bioinformatics (LBB), Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.

Background: Acute lymphoblastic leukemia (ALL) is the most common type of cancer diagnosed in children and Glucocorticoids (GCs) form an essential component of the standard chemotherapy in most treatment regimens. The category of infant ALL patients carrying a translocation involving the mixed lineage leukemia (MLL) gene (gene KMT2A) is characterized by resistance to GCs and poor clinical outcome. Although some studies examined GC-resistance in infant ALL patients, the understanding of this phenomenon remains limited and impede the efforts to improve prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s10020-019-0106-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676637PMC
August 2019
3 Reads

Clinical outcomes in allogeneic haematopoietic stem cell transplantation: A comparison between young and elderly patients. Observational study.

Eur J Cancer Care (Engl) 2019 Sep 30;28(5):e13122. Epub 2019 Jun 30.

Dayan-Daycoval Family Hematology and Oncology Center, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.

Objectives: To analyse clinical outcomes comparing two age groups of patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT), and to identify risk factors associated with older patients' mortality.

Methods: In this retrospective study, the medical charts of all consecutive patients admitted in one hospital for allo-HSCT were reviewed. Overall survival (OS) and other outcomes were compared between patients aged up to 55 years (YG) and older than 55 (EG). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ecc.13122DOI Listing
September 2019
2 Reads

SUMO-Specific Protease 1 Is Critical for Myeloid-Derived Suppressor Cell Development and Function.

Cancer Res 2019 08 11;79(15):3891-3902. Epub 2019 Jun 11.

Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Myeloid-derived suppressor cells (MDSC) can suppress immunity and promote tumorigenesis, and their abundance is associated with poor prognosis. In this study, we show that SUMO1/sentrin-specific peptidase 1 (SENP1) regulates the development and function of MDSC. SENP1 deficiency in myeloid cells promoted MDSC expansion in bone marrow, spleen, and other organs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-18-3497DOI Listing
August 2019
2 Reads

The Pluripotency Regulator PRDM14 Requires Hematopoietic Regulator CBFA2T3 to Initiate Leukemia in Mice.

Mol Cancer Res 2019 07 23;17(7):1468-1479. Epub 2019 Apr 23.

Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.

PR domain-containing 14 () is a pluripotency regulator central to embryonic stem cell identity and primordial germ cell specification. Genomic regions containing are often amplified leading to misexpression in human cancer. expression in mouse hematopoietic stem cells (HSC) leads to progenitor cell expansion prior to the development of T-cell acute lymphoblastic leukemia (T-ALL), consistent with PRDM14's role in cancer initiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-18-1327DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610658PMC
July 2019
5 Reads

[E-cadherin Expression in Children with Acute Leukemia and Its Clinical Significance].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):339-347

Department of Hematology & Oncology, Childhren's Hospital Affiliated to Chongqing Medical University; Key Laboratory of Child Development and Disorders of Ministry of Education; China International Science and Technology Cooperation Base of Child Development and Critical Disorders; Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China,E-mail:

Objective: To investigate the correlation of E-cadherin expression level with the clinical characterastics in children with acute leukemia (AL), and to explore the possible regulatory mechanism.

Methods: Real-time quantitative RT-PCR was applied to detect the expression level of E-cadherin in bone marrow samples from 135 child patients diagnosed as AL, and its relevance with clinical indicators was statistically analyzed. The expression levels of E-cadherin, β-catenin, and Akt/p-Akt were detected by using Western blot. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.005DOI Listing
April 2019
12 Reads

Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia.

Br J Haematol 2019 04 31;185(2):232-239. Epub 2019 Jan 31.

Division of Molecular Genetic Epidemiology, German Cancer Research Centre (DKFZ), Heidelberg, Germany.

Improvement of survival in lymphocytic leukaemia has been accompanied by the occurrence of second primary cancer (SPCs). Based on Swedish Family Cancer Database, we applied bi-directional analyses in which relative risks (RRs) were calculated for any SPCs in patients with chronic lymphocytic leukaemia (CLL), acute lymphoblastic leukaemia (ALL) and hairy cell leukaemia (HCL) and the risks of these leukaemias as SPCs. After CLL, RRs were significant for 20 SPCs, and high for skin squamous cell cancer (24·58 for in situ and 7·63 for invasive), Merkel cell carcinoma (14·36), Hodgkin lymphoma (7·16) and Kaposi sarcoma (6·76). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15777DOI Listing
April 2019
29 Reads

Population pharmacokinetics of lenalidomide in patients with B-cell malignancies.

Br J Clin Pharmacol 2019 05 27;85(5):924-934. Epub 2019 Feb 27.

Australian Centre for Pharmacometrics, School of Pharmacy and Medical Sciences, Division of Health Sciences, University of South Australia, Australia.

Aims: Lenalidomide is an immunomodulatory imide drug used broadly in the treatment of multiple myeloma and lymphoma. It continues to be evaluated in chronic lymphocytic leukaemia (CLL) at lower doses due to dose-related toxicities including tumour flare and tumour lysis syndrome. This study aimed to develop a population pharmacokinetic model for lenalidomide in multiple cancers, including CLL, to identify any disease-related differences in disposition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcp.13873DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475687PMC
May 2019
12 Reads

Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors.

Blood Adv 2019 01;3(2):105-115

Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan.

Antithymocyte globulin (ATG) is widely used to reduce acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD). To clarify the different impacts of ATG for conditioning across different donor types, we retrospectively analyzed patients with acute leukemia (n = 6617) who underwent hematopoietic stem cell transplantation between 2008 and 2015 with ATG (n = 279) or without ATG (n = 6338). Because thymoglobulin is the only ATG drug approved for GVHD prophylaxis in Japan since September 2008, we included thymoglobulin alone in the present analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018025643DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341193PMC
January 2019
52 Reads

[Therapeutic approaches to hematological malignancies in adolescents and young adults].

Rinsho Ketsueki 2018;59(10):2273-2283

Department of Pediatrics, National Hospital Organization Nagoya Medical Center.

Hematological malignancies (HM) comprise the major proportion of the cancer incidence and mortality in the adolescent and young adult (AYA) age group. Even though age-related differences in tumor biology have been reported in HM, further biological studies are warranted for elucidating age-related differences in AYAs. Hemato-oncologists and pediatric oncologists frequently follow various treatment strategies for HM, as the treatment strategy that is more suitable for this age group remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11406/rinketsu.59.2273DOI Listing
July 2019
4 Reads

Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients.

Haematologica 2018 10 14;103(10):1662-1668. Epub 2018 Jun 14.

Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA.

Therapy-related acute lymphoblastic leukemia remains poorly defined due to a lack of large data sets recognizing the defining characteristics of this entity. We reviewed all consecutive cases of adult acute lymphoblastic leukemia treated at our institution between 2000 and 2017 and identified therapy-related cases - defined as acute lymphoblastic leukemia preceded by prior exposure to cytotoxic chemotherapy and/or radiation. Of 1022 patients with acute lymphoblastic leukemia, 93 (9. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.193599DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165794PMC
October 2018
42 Reads

The Role of Macrophage/B-Cell Interactions in the Pathophysiology of B-Cell Lymphomas.

Front Oncol 2018 8;8:147. Epub 2018 May 8.

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Macrophages (MPs) are heterogeneous, multifunctional, myeloid-derived leukocytes that are part of the innate immune system, playing wide-ranging critical roles in basic biological activities, including maintenance of tissue homeostasis involving clearance of microbial pathogens. Tumor-associated MPs (TAMs) are MPs with defined specific M2 phenotypes now known to play central roles in the pathophysiology of a wide spectrum of malignant neoplasms. Also, TAMs are often intrinsic cellular components of the essential tumor microenvironment (TME). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2018.00147DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951963PMC
May 2018
17 Reads

Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants.

Blood Adv 2018 05;2(9):1022-1031

Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

Optimal donor selection is critical for successful allogeneic hematopoietic cell transplantation (HCT). Donor sex and parity are well-established risk factors for graft-versus-host disease (GVHD), with male donors typically associated with lower rates of GVHD. Well-matched unrelated donors (URDs) have also been associated with increased risks of GVHD as compared with matched sibling donors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2017013052DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941995PMC
May 2018
79 Reads

Applicability of 2008 World Health Organization classification system of hematolymphoid neoplasms: Learning experiences.

Indian J Pathol Microbiol 2018 Jan-Mar;61(1):58-65

Department of Pathology, Tata Memorial Hospital; Department of Pathology, Hematopathology Laboratory, Tata Memorial Hospital, Mumbai, Maharashtra, India.

Background: 2008 World Health Organization (WHO) classification of hematolymphoid neoplasms (HLN) has classified them based on morphology, results of various ancillary techniques, and clinical features. There are no studies looking at the applicability of WHO classification.

Aims: The aim of the study was to calculate proportions of all HLN subtypes seen during 1-year period based on 2008 WHO classification of HLN and study applicability and also shortcomings of practices in a tertiary care center in India. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/IJPM.IJPM_56_17DOI Listing
November 2018
50 Reads

Cell proliferation and inhibition of apoptosis are related to c-Kit activation in leukaemic lymphoblasts.

Hematology 2018 Sep 1;23(8):486-495. Epub 2018 Mar 1.

a Escuela Nacional de Ciencias Biologicas , Instituto Politecnico Nacional , Ciudad de México , Mexico.

Receptor tyrosine kinase (RTK) activity may contribute to carcinogenesis. The c-Kit receptor, a member of the RTK family, is expressed in immature haematopoietic system cells. Acute lymphoblastic leukaemia (ALL) presents incompletely differentiated lymphoblasts, and consequently, c-Kit expression can be detected in these cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10245332.2018.1444564DOI Listing
September 2018
48 Reads

Ponatinib for Treating Chronic Myeloid Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Pharmacoeconomics 2018 08;36(8):903-915

School of Health and Related Research, University of Sheffield, Sheffield, S1 4DA, UK.

As part of its single technology appraisal process, the National Institute for Health and Care Excellence (NICE) invited the company that manufactures ponatinib (Inclusig; Incyte Corporation) to submit evidence for the clinical and cost effectiveness for previously treated chronic myeloid leukaemia (CML) and Philadelphia-chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL). This paper focusses on the three phases of CML: the chronic phase (CP), the accelerated phase (AP) and the blast crisis phase (BP). The School of Health and Related Research Technology Appraisal Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group (ERG). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40273-018-0627-4DOI Listing
August 2018
14 Reads

Efficacy and safety of voriconazole in immunocompromised patients: systematic review and meta-analysis.

Infect Dis (Lond) 2018 07 20;50(7):489-494. Epub 2017 Dec 20.

e Universidad Abierta Interamericana (UAI), CABA , Buenos Aires , Argentina.

Background: Voriconazole is a second-generation triazole. It has excellent bioavailability and broad antifungal spectrum; thus, it is an attractive option for patients at high risk of invasive fungal infections (IFIs). Comparing efficacy and safety of voriconazole with other antifungals in prophylaxis or treatment of IFIs would be useful to draw conclusions regarding prevention and therapeutics of these infections. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/23744235.2017.1418531DOI Listing
July 2018
18 Reads

Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant.

Blood 2017 09 15;130(13):1585-1596. Epub 2017 Aug 15.

College of Pharmacy, The Ohio State University, Columbus, OH.

Multiple candidate gene-association studies of non-HLA single-nucleotide polymorphisms (SNPs) and outcomes after blood or marrow transplant (BMT) have been conducted. We identified 70 publications reporting 45 SNPs in 36 genes significantly associated with disease-related mortality, progression-free survival, transplant-related mortality, and/or overall survival after BMT. Replication and validation of these SNP associations were performed using DISCOVeRY-BMT (Determining the Influence of Susceptibility COnveying Variants Related to one-Year mortality after BMT), a well-powered genome-wide association study consisting of 2 cohorts, totaling 2888 BMT recipients with acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome, and their HLA-matched unrelated donors, reported to the Center for International Blood and Marrow Transplant Research. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-05-784637DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620418PMC
September 2017
82 Reads

The Effect of Dose-Volume Parameters on Central Nervous System Relapse in Pediatric Patients with Acute Leukemia Receiving Prophylactic Cranial Irradiation.

Gulf J Oncolog 2017 May;1(24):24-29

Dept of Radiation Oncology, Dokuz Eylül Univ Faculty of Medicine, Izmir, Turkey.

Aim Of The Study: To investigate the effects of dosevolume parameters of brain parenchyma, optic nerves (ONs) and cribriform plate (CP), which were determined on central nervous system (CNS) control in pediatric leukemia patients who have undergone prophylactic cranial irradiation (PCI) at our department.

Patients And Methods: In the current study, the records of 14 patients were examined retrospectively. Along with the minimum and maximum doses for brain and CP, D95% (minimal dose received by the 95% volume of a structure) and V95% (percent volume of target receiving 95% of prescribed dose) could be obtained from the dose-volume histogram. Read More

View Article

Download full-text PDF

Source
May 2017
18 Reads

Tumor-forming plasmacytoid dendritic cells in acute myelocytic leukemia: a report of three cases and literature review.

Int J Clin Exp Pathol 2017 1;10(7):7285-7291. Epub 2017 Jul 1.

The Department of Hematology in Xinqiao Hospital, Third Military Medical University Chongqing, China.

Plasmacytoid dendritic cells (PDCs), through their production of type I interferons (IFNs) and other pro-inflammatory cytokines, link the innate and adaptive immunity, and provide anti-viral resistance. It is reported PDCs accumulated in inflammatory and human neoplasms, including hematopoietic malignancies. To date, the clinical significance of tumor-forming PDCs (TF-PDCs) in AML is largely unknown. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965252PMC

Benzene and childhood acute leukemia in Oklahoma.

Environ Res 2017 10 20;158:167-173. Epub 2017 Jun 20.

Department of Biostatistics and Epidemiology, College of Public Health, University of Oklahoma Health Sciences Center, 801 NE 13th St., CHB 309, Oklahoma City, OK 73104, USA. Electronic address:

Background: Although childhood cancer is a leading cause of childhood mortality in the US, evidence regarding the etiology is lacking. The goal of this study was to evaluate the association between benzene, a known carcinogen, and childhood acute leukemia.

Methods: We conducted a case-control study including cases diagnosed with acute leukemia between 1997 and 2012 (n = 307) from the Oklahoma Central Cancer Registry and controls matched on week of birth from birth certificates (n = 1013). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.envres.2017.06.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554454PMC
October 2017
53 Reads

[Correlation between Dynamic Change of IL-32 Level and Disease Development in Acute Leukemia Patients].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2017 Jun;25(3):688-692

Department of Clinical Laboratorial Examination, Hainan Provincial People's Hospital, Haikou 570102, Hainan Province, China.

Objective: To investigate the correlation between dynamic change of IL-32 level and disease development in the patients with acute leukemia(AL) and to explore its clinical significance.

Methods: The serum IL-32 levels and IL-32 mRNA expression in 82 cases of AL and 30 healthy persons were measured by ELISA and real-time PCR.

Results: Compared with healthy persons, the serum IL-32 protein level and IL-32 mRNA expression in AL, acute lymphoblastic leukemia(ALL) and acute non-lymphocytic leukemia(ANLL) groups all were significantly higher(P<0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2017.03.010DOI Listing
June 2017
11 Reads

Environmental Exposure and Risk of Childhood Leukemia: An Overview.

Arch Med Res 2016 11;47(8):607-614

International Agency for Research on Cancer, Section of Environment and Radiation, Lyon, France; Danish Cancer Society Research Center, Unit of Survivorship, Copenhagen, Denmark.

Childhood leukemia is the most common cancer diagnosed in children worldwide. However, only a few causes have been established so far, mainly some genetic syndromes and high doses of ionizing radiation. Major efforts have been undertaken to study the relationship between environmental factors and the risk of childhood leukemia, inspired by geographical variation in incidence rates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.arcmed.2016.11.017DOI Listing
November 2016
25 Reads

The effect of inter-unit HLA matching in double umbilical cord blood transplantation for acute leukemia.

Haematologica 2017 05 25;102(5):941-947. Epub 2017 Jan 25.

Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA

The effects of inter-unit HLA-match on early outcomes with regards to double cord blood transplantation have not been established. Therefore, we studied the effect of inter-unit HLA-mismatching on the outcomes of 449 patients with acute leukemia after double cord blood transplantation. Patients were divided into two groups: one group that included transplantations with inter-unit mismatch at 2 or less HLA-loci (n=381) and the other group with inter-unit mismatch at 3 or 4 HLA-loci (n=68). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2016.158584DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477613PMC
May 2017
53 Reads

Network-based expression analysis reveals key genes related to glucocorticoid resistance in infant acute lymphoblastic leukemia.

Cell Oncol (Dordr) 2017 Feb 31;40(1):33-45. Epub 2016 Oct 31.

Laboratory of Systems Biology and Bioinformatics (LBB), Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.

Purpose: Despite vast improvements that have been made in the treatment of children with acute lymphoblastic leukemia (ALL), the majority of infant ALL patients (~80 %, < 1 year of age) that carry a chromosomal translocation involving the mixed lineage leukemia (MLL) gene shows a poor response to chemotherapeutic drugs, especially glucocorticoids (GCs), which are essential components of all current treatment regimens. Although addressed in several studies, the mechanism(s) underlying this phenomenon have remained largely unknown. A major drawback of most previous studies is their primary focus on individual genes, thereby neglecting the putative significance of inter-gene correlations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13402-016-0303-7DOI Listing
February 2017
37 Reads

Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias.

Am J Hematol 2017 Jan 7;92(1):7-11. Epub 2016 Dec 7.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Phosphatidylinositol-3-kinase (PI3K) signaling plays a crucial role in oncogene-mediated tumor growth and proliferation. Buparlisib (BKM120) is an oral pan-class I PI3K inhibitor. This phase I study was conducted to determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of BKM120 in patients (pts) with relapsed/refractory acute leukemias. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24568DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361214PMC
January 2017
87 Reads

Cord-Blood Transplantation in Patients with Minimal Residual Disease.

N Engl J Med 2016 Sep;375(10):944-53

From the Clinical Research Division, Fred Hutchinson Cancer Research Center (F.M., T.G., A.W., M.E.F., K.D., R.W., M.M., J.H.D., M.S., A.D., B.M.S., R.S., E.P., F.R.A., C.D.), and the Departments of Medicine (F.M., B.W., M.E.F., M.M., J.H.D., M.S., B.M.S., R.S., E.P., F.R.A.) and Pediatrics (A.W., A.D., C.D.), University of Washington - both in Seattle.

Background: The majority of patients in need of a hematopoietic-cell transplant do not have a matched related donor. Data are needed to inform the choice among various alternative donor-cell sources.

Methods: In this retrospective analysis, we compared outcomes in 582 consecutive patients with acute leukemia or the myelodysplastic syndrome who received a first myeloablative hematopoietic-cell transplant from an unrelated cord-blood donor (140 patients), an HLA-matched unrelated donor (344), or an HLA-mismatched unrelated donor (98). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1602074DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513721PMC
September 2016
47 Reads

The molecular signature of AML mesenchymal stromal cells reveals candidate genes related to the leukemogenic process.

Cancer Lett 2015 Dec 13;369(1):134-43. Epub 2015 Aug 13.

Stem Cell Laboratory, Bone Marrow Transplantation Unit, National Cancer Institute (INCA), Rio de Janeiro, RJ, Brazil; Instituto Nacional de Ciência e Tecnologia Para o Controle do Câncer (INCT), Rio de Janeiro, RJ, Brazil.

Acute myeloid leukemia (AML) is a heterogeneous disease characterized by myeloid precursor proliferation in the bone marrow, apoptosis reduction and differentiation arrest. Although there are several studies in this field, events related to disease initiation and progression remain unknown. The malignant transformation of hematopoietic stem cells (HSC) is thought to generate leukemic stem cells, and this transformation could be related to changes in mesenchymal stromal cell (hMSC) signaling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2015.08.006DOI Listing
December 2015
42 Reads

B-acute lymphoblastic leukemia/lymphoblastic lymphoma.

Am J Clin Pathol 2015 Sep;144(3):393-410

From the Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston; and

Objectives: This session of the 2013 Society of Hematopathology/European Association for Haematopathology Workshop was dedicated to B-acute lymphoblastic leukemia (B-ALL)/lymphoblastic lymphoma (LBL) with recurrent translocations and not otherwise specified.

Methods: In this review, we summarize the cases discussed during the workshop, review the pertinent and most recent literature on the respective topics, and provide a few key points that may aid in the workup of patients with B-ALL/LBL.

Results: Many of the submitted cases showed interesting diagnostic, immunophenotypic, or clinical aspects of B-ALL with BCR/ABL1, MLL-associated, and other recurrent chromosomal abnormalities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1309/AJCPAN7BH5DNYWZBDOI Listing
September 2015
9 Reads

Blastic plasmacytoid dendritic cell neoplasm presenting as leukemia without cutaneous involvement in a 25 years male patient: Unusual presentation of a rare entity.

Indian J Pathol Microbiol 2015 Jul-Sep;58(3):377-80

Department of Hematology, SGPGI, Lucknow, Uttar Pradesh, India.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive neoplasm classified under "acute myeloid leukemia (AML) and related precursor neoplasm" by current WHO classification. Elderly male are commonly affected with cutaneous lesion being the hallmark of disease presentation. The disease progresses rapidly and sooner or later involves bone marrow and peripheral blood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/0377-4929.162912DOI Listing
April 2016
37 Reads
0.642 Impact Factor

Can the KG1 cell line be used as a model of dendritic cells and discriminate the sensitising potential of chemicals?

Toxicol Lett 2015 Nov 7;239(1):32-40. Epub 2015 Aug 7.

Health and Safety Laboratory, Harpur Hill, Buxton, Derbyshire SK17 9JN, UK. Electronic address:

The KG1 myeloid leukaemia was used as source of dendritic cells (DC) to discriminate between respiratory and contact sensitising chemicals. A cocktail of cytokines was used to differentiate KG1 to dendritic like cells (termed dKG1) and the effects of nine chemicals (respiratory and contact sensitisers) and an irritant control on surface marker expression, 'antigen presenting' function and cytokine expression investigated. The stability of these chemicals when dissolved was characterised using MALDI ToF MS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.toxlet.2015.08.006DOI Listing
November 2015
41 Reads

Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.

Biol Blood Marrow Transplant 2015 Nov 26;21(11):2008-16. Epub 2015 Jul 26.

Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.

Cytomegalovirus (CMV) infection is a major infectious complication after allogeneic hematopoietic cell transplantation (allo-HSCT). Recently, it was reported that CMV reactivation is associated with a decreased risk of relapse in patients with acute myeloid leukemia (AML). The aim of this study was to evaluate the impact of early CMV reactivation on the incidence of disease relapse after allo-HSCT in a large cohort of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2015.07.019DOI Listing
November 2015
100 Reads

Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.

Am J Hematol 2015 Sep 1;90(9):755-68. Epub 2015 Jun 1.

Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.

Long-term efficacy and safety of bosutinib (≥4 years follow-up from last enrolled patient) were evaluated in an ongoing phase 1/2 study in the advanced leukemia cohort with prior treatment failure (accelerated-phase [AP, n = 79] chronic myeloid leukemia [CML], blast-phase [BP, n = 64] CML, acute lymphoblastic leukemia [ALL, n = 24]). Fourteen AP, 2 BP, and 1 ALL patient remained on bosutinib at 4 years (vs. 38, 8, 1 at 1 year); median (range) treatment durations: 10. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24034DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5132035PMC
September 2015
37 Reads

Long noncoding RNA, CCDC26, controls myeloid leukemia cell growth through regulation of KIT expression.

Mol Cancer 2015 Apr 19;14:90. Epub 2015 Apr 19.

Domain of Life Sciences, Graduate School of Integrated Arts and Sciences, Hiroshima University, 1-7-1 Kagamiyama, Higashihiroshima, Hiroshima, 739-8521, Japan.

Background: Accumulating evidence suggests that some long noncoding RNAs (lncRNAs) are involved in certain diseases, such as cancer. The lncRNA, CCDC26, is related to childhood acute myeloid leukemia (AML) because its copy number is altered in AML patients.

Results: We found that CCDC26 transcripts were abundant in the nuclear fraction of K562 human myeloid leukemia cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12943-015-0364-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423487PMC
April 2015
14 Reads

Bloodstream infection in paediatric cancer centres--leukaemia and relapsed malignancies are independent risk factors.

Eur J Pediatr 2015 May 26;174(5):675-86. Epub 2015 Mar 26.

Department of Paediatrics, University of Bern, Bern, Switzerland,

Unlabelled: In a prospective multicentre study of bloodstream infection (BSI) from November 01, 2007 to July 31, 2010, seven paediatric cancer centres (PCC) from Germany and one from Switzerland included 770 paediatric cancer patients (58% males; median age 8.3 years, interquartile range (IQR) 3.8-14. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00431-015-2525-5
Publisher Site
http://dx.doi.org/10.1007/s00431-015-2525-5DOI Listing
May 2015
28 Reads

Therapy-related myelodysplastic syndrome.

Expert Opin Drug Saf 2015 May 12;14(5):655-65. Epub 2015 Feb 12.

Instituto Nacional de Cancerología Mexico , Ave. San Fernando 22, Seccion XVI, Tlalpan, Mexico City , Mexico.

Introduction: Myelodysplastic syndrome (MDS) is a heterogeneous clonal disorder characterized by deregulation of apoptosis, dysplastic features in hematopoietic precursors, peripheral blood cytopenias and an increased risk for transformation to acute leukemia. Roughly 20% of MDS are therapy related (t-MDS), and this is considered an independent adverse prognostic factor.

Areas Covered: This review based on a comprehensive literature search provides an overview on the main features of t-MDS, including its epidemiology, risk factors, molecular pathogenesis, prognostic classifications and therapy. Read More

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/content/78/11/2982.full.pdf
Web Search
http://annonc.oxfordjournals.org/content/13/3/450.full.pdf
Web Search
http://ajcp.oxfordjournals.org/content/ajcpath/127/2/197.ful
Web Search
http://www.tandfonline.com/doi/full/10.1517/14740338.2015.10
Publisher Site
http://dx.doi.org/10.1517/14740338.2015.1014340DOI Listing
May 2015
13 Reads

Frequency, risk factors, and outcomes of vancomycin-resistant Enterococcus colonization and infection in patients with newly diagnosed acute leukemia: different patterns in patients with acute myelogenous and acute lymphoblastic leukemia.

Infect Control Hosp Epidemiol 2015 Jan;36(1):47-53

2Division of Infectious Diseases,LDS Hospital and the University of Utah,Salt Lake City,Utah.

OBJECTIVE To determine the frequency, risk factors, and outcomes for vancomycin-resistant Enterococcus (VRE) colonization and infection in patients with newly diagnosed acute leukemia. DESIGN Retrospective clinical study with VRE molecular strain typing. SETTING A regional referral center for acute leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/ice.2014.3DOI Listing
January 2015
24 Reads

[Increased risk of severe acute graft-versus-host disease in low body mass index patients undergoing haploidentical allogeneic stem cell transplantation].

Zhonghua Nei Ke Za Zhi 2014 Sep;53(9):710-4

Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, People's Hospital, Peking University, Beijing 100044, China. Email:

Objective: To investigate the impact of body mass index (BMI) before transplantation on clinical outcomes of haploidentical allogeneic stem cell transplantation (allo-HSCT).

Methods: We performed a retrospective cohort study of 253 adult patients with acute or chronic leukemia who received haploidentical allo-HSCT from August 2008 to September 2011. All conditioning regimens were myeloablative and bulsufan based. Read More

View Article

Download full-text PDF

Source
September 2014
56 Reads

Non transferrin bound iron (NTBI) in acute leukemias throughout conventional intensive chemotherapy: kinetics of its appearance and potential predictive role in infectious complications.

Leuk Res 2015 Jan 15;39(1):88-91. Epub 2014 Nov 15.

Department of Medicine and Medical Specialities, "Ca' Granda" Foundation IRCCS, University of Milan, Via F. Sforza 35, 20122 Milano, Italy. Electronic address:

We analyzed appearance of non transferrin bound iron (NTBI) in 30 transplant eligible patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) during conventional chemotherapy treatment program and evaluated possible relationship with transfusional body iron intake, iron parameters and clinical complications. For each course, serum samples for NTBI detection were taken prior to chemotherapy, during treatment and during subsequent bone marrow myelosuppression: NTBI was assessed by HPLC. Appearance of NTBI was observed from the start of induction treatment and was still detectable during bone marrow myelosuppression; the recovery of the bone marrow function coincided with the disappearance of NTBI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2014.11.003DOI Listing
January 2015
44 Reads

Homozygous inv(11)(q21q23) and MLL gene rearrangement in two patients with myeloid neoplasms.

Int J Clin Exp Pathol 2014 15;7(6):3196-201. Epub 2014 May 15.

Department of Molecular and Human Genetics, Baylor College of Medicine Houston, TX 77030, USA.

Rearrangements of the MLL gene located at chromosome 11q23 are common chromosomal abnormalities associated with acute leukemias. In vast majority of cases with MLL gene rearrangements, only one chromosome 11 or a single MLL allele got involved. We report two very unusual cases of myeloid neoplasms with homozygous inv(11)(q21q23) and biallelic MLL rearrangement. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4097224PMC
May 2015
32 Reads

Diagnostic value of CD117 in differential diagnosis of acute leukemias.

Tumour Biol 2014 Jul 11;35(7):6763-8. Epub 2014 Apr 11.

Cellular and Molecular Research Center, Kurdistan University of Medical Sciences, Pasdaran Boulevard, Sanandaj, Iran,

C-kit receptor (CD117) and its ligand, stem cell factor, play a key role in normal hematopoiesis. It has been demonstrated that its expression extremely increases in leukemias with myeloid commitment. We analyzed findings on CD117 expression together with other myeloid related markers in 203 de novo acute leukemias, referred to Iranian immunophenotyping centers: Iranian Blood Transfusion Organization (IBTO) and Baghiatallah Hospital (BH). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s13277-014-1899
Web Search
http://link.springer.com/10.1007/s13277-014-1899-8
Publisher Site
http://dx.doi.org/10.1007/s13277-014-1899-8DOI Listing
July 2014
26 Reads
3 Citations
2.840 Impact Factor

A distinct set of long non-coding RNAs in childhood MLL-rearranged acute lymphoblastic leukemia: biology and epigenetic target.

Hum Mol Genet 2014 Jun 31;23(12):3278-88. Epub 2014 Jan 31.

Key Laboratory of Gene Engineering of the Ministry of Education, State Key Laboratory for Biocontrol, School of Life Science, Sun Yat-sen University, Guangzhou 510275, China and

Long non-coding RNAs (lncRNAs) have been recently found to be pervasively transcribed in human genome and link to diverse human diseases. However, the expression patterns and regulatory roles of lncRNAs in hematopoietic malignancies have not been reported. Here, we carried out a genome-wide lncRNA expression study in MLL-rearranged acute lymphoblastic leukemia (MLL-r ALL) and established lncRNA/messenger RNA coexpression networks to gain insight into the biological roles of these dysregulated lncRNAs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/hmg/ddu040DOI Listing
June 2014
91 Reads

Risk of leukemia in relation to exposure to ambient air toxics in pregnancy and early childhood.

Int J Hyg Environ Health 2014 Jul 25;217(6):662-8. Epub 2013 Dec 25.

Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, CA, USA.

There are few established causes of leukemia, the most common type of cancer in children. Studies in adults suggest a role for specific environmental agents, but little is known about any effect from exposures in pregnancy to toxics in ambient air. In our case-control study, we ascertained 69 cases of acute lymphoblastic leukemia (ALL) and 46 cases of acute myeloid leukemia (AML) from California Cancer Registry records of children Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijheh.2013.12.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4071125PMC
July 2014
52 Reads

c-Src activation through a TrkA and c-Src interaction is essential for cell proliferation and hematological malignancies.

Biochem Biophys Res Commun 2013 Nov 26;441(2):431-7. Epub 2013 Oct 26.

Department of Molecular Medicine, School of Medicine, Gachon University, Incheon 406-840, Republic of Korea; Gachon Medical Research Institute, Gil Medical Center, Incheon 405-760, Republic of Korea. Electronic address:

Although the kinase receptor TrkA may play an important role in acute myeloid leukemia (AML), its involvement in other types of leukemia has not been reported. Furthermore, how it contributes to leukemogenesis is unknown. Here, we describe a molecular network that is important for TrkA function in leukemogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2013.10.082DOI Listing
November 2013
30 Reads

Statins and cancer.

Anticancer Agents Med Chem 2014 Jun;14(5):706-12

5 Pyramidon str 190 05, Municipality of Marathon, Athens, Greece.

Statins have pleiotropic properties and might exert an effect even in the field of cancer. Statins competitively inhibit 3-hydroxy-3-methylglutaryl coenzyme (HMG-CoA) reductase, the major rate-limiting enzyme that controls the conversion of HMG-CoA to mevalonic acid. Specifically, inhibition of HMG-CoA reductase by statins has been proved to prevent the synthesis of mevalonic acid, a precursor of non-steroidal isoprenoids, which are lipid attachment molecules for small G proteins, such as Ras, Rho and Rac. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1871520613666131129105035DOI Listing
June 2014
35 Reads

Cryptic FUS-ERG fusion identified by RNA-sequencing in childhood acute myeloid leukemia.

Oncol Rep 2013 Dec 25;30(6):2587-92. Epub 2013 Sep 25.

Section for Cancer Cytogenetics, Institute for Medical Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.

Sequential combination of cytogenetics and RNA-sequencing (RNA-Seq) has been shown to be an efficient approach to detect pathogenetically important fusion genes in neoplasms carrying only one or a few chromosomal rearrangements. We performed RNA-Seq on an acute myeloid leukemia in a 2-year-old girl with the karyotype 46,XX,add(1)(p36), der(2)t(2;3)(q21;q21),del(3)(q21),der(10)t(1;10)(q32;q24),der(16)(2qter-->2q21::16p11-->16q24::16p11-->16pter)[13]/46,XX[2] and identified a cryptic FUS/ERG fusion gene. PCR and direct sequencing verified the presence of the FUS-ERG chimeric transcript in which exon 7 of FUS from 16p11 (nt 904 in sequence with accession number NM_004960 version 3) was fused in frame to exon 8 of ERG from sub-band 21q22. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/or.2013.2751DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3839954PMC
December 2013
47 Reads

Testicular myeloid sarcoma: case report.

Rev Bras Hematol Hemoter 2013 ;35(1):68-70

Hospital Dr. Amaral Carvalho, Jaú, SP, Brazil.

Myeloid sarcomas are extramedullary solid tumors composed of immature granulocytic precursor cells. In association with acute myeloid leukemia and other myeloproliferative disorders, they may arise concurrently with compromised bone marrow related to acute myeloid leukemia, as a relapsed presentation, or occur as the first manifestation. The testicles are considered to be an uncommon site for myeloid sarcomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5581/1516-8484.20130018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3621639PMC
April 2013
14 Reads

Childhood infectious diseases and risk of leukaemia in an adult population.

Int J Cancer 2013 Oct 6;133(8):1892-9. Epub 2013 Jul 6.

Unit of Epidemiology, Biostatistics and Clinical Trials, IRCCS AOU San Martino-IST, Genoa, Italy.

Our study is aimed at investigating the association between common childhood infectious diseases (measles, chickenpox, rubella, mumps and pertussis) and the risk of developing leukaemia in an adult population. A reanalysis of a large population-based case-control study was carried out. Original data included 1,771 controls and 649 leukaemia cases from 11 Italian areas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.28205DOI Listing
October 2013
33 Reads

Distinct clinical features of infectious complications in adult T cell leukemia/lymphoma patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis in the Nagasaki transplant group.

Biol Blood Marrow Transplant 2013 Apr 17;19(4):607-15. Epub 2013 Jan 17.

Department of Hematology, Sasebo City General Hospital, Sasebo, Japan.

Although allogeneic hematopoietic stem cell transplantation (allo-SCT) is performed as a curative option in adult T cell leukemia-lymphoma (ATL) patients, its high transplantation-related mortality raises a serious issue. The clinical features of infectious complications after transplantation are not well known. To analyze the impact of infections after allo-SCT for ATL, we retrospectively compared infectious complications in 210 patients at 3 institutions in Nagasaki prefecture between 1997 and 2009. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2013.01.011DOI Listing
April 2013
55 Reads